Hereditary hemorrhagic telangiectasia is a rare multisystem vascular disorder. Also known as Rendu Osler syndrome, it is characterized by mucocutaneous telangiectases, epistaxis, gastrointestinal bleeding, and visceral arteriovenous malformations.
A sixty-two-year old male patient was followed due to hereditary hemorrhagic telangiectasia. Because of high transfusion dependency he received bevacizumab administration at a dose of 5 mg/kg every 2 weeks, for a total of eight cycles. We achieved considerable response in terms of the dependency of transfusion after bevacizumab treatment. Serum and tissue expression of vascular endothelial growth factor is increased in patients with hereditary hemorrhagic telangiectasia. Thus, logically, vascular endothelial growth factor inhibitors could be expected to function in the therapy of hereditary hemorrhagic telangiectasia as well.
Hereditary Hemorrhagic Telangiectasia; Bleeding; Bevacizumab.